Drug intelligence / Profile preview

Xinnaoqing Soft Capsules

Development stage: Unknown
Lead developer: China Shineway Pharmaceutical Group
Administration: Oral

Overview

Xinnaoqing Soft Capsules is a Traditional Chinese Medicine (TCM) product developed and manufactured by Shanghai Shyndec Pharmaceutical. It is primarily indicated for the treatment of coronary heart disease and symptoms related to cerebral arteriosclerosis. As a TCM formulation, it is designed to promote blood circulation, resolve blood stasis, and improve blood flow to the cardiovascular and cerebrovascular systems. The drug is formulated as a soft capsule for oral administration and has received regulatory approval in China.

Brand names: Xinnaoqing Soft Capsules
Other names: 心脑清软胶囊Xinnaoqing Ruanjiaonang

Beyond the preview

Go deeper on Xinnaoqing Soft Capsules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xinnaoqing Soft Capsules.

Explore the full profile